CoChat
Sign Up
Cited by 57Dermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisSystemic Sclerosis and Related Diseases

Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases

Open access
Seremet, Teofila, Di Domizio, Jeremy, Girardin, Antoine, Yatim, Ahmad, Jenelten, Raphael, Messina, Francesco, Saidoune, Fanny, Schlapbach, Christoph +14 more·2024·Nature Communications
DOI 10.1038/s41467-024-54559-6PMC PMC11655867
Open this paper in CoChat — free accountOpen PDF

Abstract

Previous advances have identified immune pathways associated with inflammatory skin diseases, leading to the development of targeted therapies. However, there is a lack of molecular approaches that delineate these pathways at the individual patient level for personalized diagnostic and therapeutic guidance. Here, we conduct a cross-comparison of expression profiles from multiple inflammatory skin diseases to identify gene modules defining relevant immune pathways. Seven modules are identified, representing key immune pathways: Th17, Th2, Th1, Type I IFNs, neutrophilic, macrophagic, and eosinophilic. These modules allow the development of a molecular map with high diagnostic efficacy for inflammatory skin diseases and clinico-pathologically undetermined cases. Aligning dominant modules with treatment targets offers a rational framework for treatment selection, improving response rates in both treatment-naïve patients and non-responders to targeted therapies. Overall, our approach offers precision medicine for inflammatory skin diseases, utilizing transcriptional modules to support diagnosis and guide personalized treatment selection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-54559-6

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Transcriptomics classified CLE and identified genes related to type 1 IFN-mediated inflammation (TLR3, MYD88, IRF7), STAT2 and PRF1, or IFN stimulation (such as CXCL9, CCL8, ISG15).

    “One notable study utilized transcriptomics to classify CLE, identifying associated genes related to type 1 IFN—mediated inflammation (TLR3, MYD88, IRF7), STAT2 and PRF1, or IFN stimulation (such as CXCL9, CCL8, ISG15) (Seremet et al, 2024).”

    From Artificial intelligence–enabled precision medicine for inflammatory skin diseases (2026) · cites this paper as Seremet et al, 2024

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. [1]Mosmann, T. R. & Coffman, R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev. Immunol. 7, 145–173 (1989). 2523712 · DOI · Paper page
  2. [2]Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. Annu Rev. Immunol. 27, 485–517 (2009). 19132915 · DOI · Paper page
  3. [3]Sakaguchi, S. et al. Regulatory T Cells and Human Disease. Annu Rev. Immunol. 38, 541–566 (2020). 32017635 · DOI
  4. [4]Theofilopoulos, A. N., Baccala, R., Beutler, B. & Kono, D. H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev. Immunol. 23, 307–336 (2005). 15771573 · DOI
  5. [6]Nestle, F. O., Kaplan, D. H. & Barker, J. Psoriasis. N. Engl. J. Med 361, 496–509 (2009). 19641206 · DOI
  6. [7]Lowes, M. A., Suarez-Farinas, M. & Krueger, J. G. Immunology of psoriasis. Annu Rev. Immunol. 32, 227–255 (2014). 24655295 PMC4229247 · DOI
  7. [8]Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E. & Barker, J. Psoriasis. Lancet 397, 1301–1315 (2021). 33812489 · DOI
  8. [9]Bieber, T. Atopic dermatitis. N. Engl. J. Med 358, 1483–1494 (2008). 18385500 · DOI · Paper page
  9. [10]Brunner, P. M., Guttman-Yassky, E. & Leung, D. Y. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J. Allergy Clin. Immunol. 139, S65–S76 (2017). 28390479 PMC5405702 · DOI
  10. [12]Shao, S. et al. IFN-gamma enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci. Transl. Med.11, eaav7561 (2019). PMC7285657 31554739
  11. [13]Caielli, S., Wan, Z. & Pascual, V. Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. Annu Rev. Immunol. 41, 533–560 (2023). 36854182 · DOI
  12. [14]Wallace, D. J. Progress toward Better Treatment of Lupus. N. Engl. J. Med 387, 939–940 (2022). 36069878 · DOI
  13. [15]Satoh, T. K., Mellett, M., Contassot, E. & French, L. E. Are neutrophilic dermatoses autoinflammatory disorders? Br. J. Dermatol 178, 603–613 (2018). 27905098 · DOI
  14. [16]Papp, K. A. et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N. Engl. J. Med 376, 1551–1560 (2017). 28423301 · DOI
  15. [17]Reich, K. et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 390, 276–288 (2017). 28596043 · DOI
  16. [18]Reich, K. et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 394, 831–839 (2019). 31402114 · DOI
  17. [20]Gordon, K. B., Colombel, J. F. & Hardin, D. S. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N. Engl. J. Med 375, 2102 (2016). 27959738 · DOI
  18. [21]Gordon, K. B. et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 397, 475–486 (2021). 33549192 · DOI
  19. [24]Silverberg, J. I. et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N. Engl. J. Med 388, 1080–1091 (2023). 36920778 · DOI
  20. [25]Damsky, W. et al. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. J. Allergy Clin. Immunol. 145, 1708–1710 e1702 (2020). 32018031 · DOI
  21. [26]Boll, S. L., Zahn, C. A. & Schlapbach, C. Rapid and sustained improvement of cutaneous lichen planus with oral JAK1 inhibitors. J. Eur. Acad. Dermatol Venereol. 38, e82–e85 (2024). 37595958 · DOI
  22. [27]Morand, E. F. et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N. Engl. J. Med 382, 211–221 (2020). 31851795 · DOI
  23. [28]Brenner, M., Ruzicka, T., Plewig, G., Thomas, P. & Herzer, P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br. J. Dermatol 161, 1199–1201 (2009). 19673875 · DOI
  24. [29]Delluc, A. et al. Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann. Rheum. Dis. 67, 278–279 (2008). 18192308 · DOI
  25. [30]Tzanetakou, V. et al. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. JAMA Dermatol 152, 52–59 (2016). 26579854 · DOI
  26. [31]Bachelez, H. et al. Trial of Spesolimab for Generalized Pustular Psoriasis. N. Engl. J. Med 385, 2431–2440 (2021). 34936739 · DOI
  27. [32]Guenin, S. H., Khattri, S. & Lebwohl, M. G. Spesolimab use in treatment of pyoderma gangrenosum. JAAD Case Rep. 34, 18–22 (2023). 36936866 PMC10015112 · DOI
  28. [33]Alavi, A. Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study. SKIN J. Cutan. Med. 7, s286 (2023). · DOI
  29. [34]Inkeles, M. S. et al. Comparison of molecular signatures from multiple skin diseases identifies mechanisms of immunopathogenesis. J. Invest Dermatol 135, 151–159 (2015). 25111617 PMC4268388 · DOI
  30. [35]Aevermann, B. D. et al. Cross-Comparison of Inflammatory Skin Disease Transcriptomics Identifies PTEN as a Pathogenic Disease Classifier in Cutaneous Lupus Erythematosus. J. Invest Dermatol 144, 252–262.e254 (2024). 37598867 · DOI
  31. [37]Collins, F. S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med 372, 793–795 (2015). 25635347 PMC5101938 · DOI · Paper page
  32. [38]Gilliet, M. Targeted therapies and precision medicine for inflammatory skin diseases. Eur. J. Dermatol 29, 19–24 (2019). 30973332 · DOI
  33. [39]Distler, O., Ludwig, R. J., Niemann, S., Riemekasten, G. & Schreiber, S. Editorial: Precision Medicine in Chronic Inflammation. Front Immunol. 12, 770462 (2021). 34630441 PMC8495129 · DOI
  34. [40]Talamonti, M. et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br. J. Dermatol 169, 458–463 (2013). 23521149 · DOI
  35. [41]Li, K. et al. HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program. J. Invest Dermatol 136, 2364–2371 (2016). 27476722 · DOI
  36. [42]Costanzo, A. et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br. J. Dermatol 179, 1072–1080 (2018). 29704432 · DOI
  37. [43]Garzorz-Stark, N. et al. A novel molecular disease classifier for psoriasis and eczema. Exp. Dermatol 25, 767–774 (2016). 27193975 · DOI
  38. [44]Liu, Y. et al. Classification of human chronic inflammatory skin disease based on single-cell immune profiling. Sci. Immunol. 7, eabl9165 (2022). 35427179 PMC9301819 · DOI
  39. [45]Schabitz, A. et al. Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseases. Nat. Commun. 13, 7729 (2022). 36513651 PMC9747967 · DOI
  40. [46]Conrad, C. et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat. Commun. 9, 25 (2018). 29295985 PMC5750213 · DOI
  41. [47]Zhao, L. et al. Evaluation of Dupilumab in Patients With Bullous Pemphigoid. JAMA Dermatol 159, 953–960 (2023). 37531116 PMC10398542 · DOI
  42. [48]Czarnowicki, T., He, H., Krueger, J. G. & Guttman-Yassky, E. Atopic dermatitis endotypes and implications for targeted therapeutics. J. Allergy Clin. Immunol. 143, 1–11 (2019). 30612663 · DOI
  43. [49]Conrad, C. & Gilliet, M. Psoriasis: from Pathogenesis to Targeted Therapies. Clin. Rev. Allergy Immunol. 54, 102–113 (2018). 29349534 · DOI

Cited by

Sorted by citations

Authors
Seremet, T., Di Domizio, J., Girardin, A., Yatim, A., Jenelten, R., Messina, F., Saidoune, F., Schlapbach, C., Bogiatzi, S., Minisini, F., Garzorz-Stark, N., Leuenberger, M., Wüthrich, H., Vernez, M., Hohl, D., Eyerich, S., Eyerich, K., Guenova, E., Paul, C., Gottardo, R., Conrad, C., & Gilliet, M.
Affiliations
  • Centre Hospitalier Universitaire Vaudois (CH)
  • University of Bern (CH)
  • University of Freiburg (DE)
  • Centre Hospitalier Universitaire de Toulouse (FR)
Corresponding author
Gilliet, Michel
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2024-12-18
Volume
15
Issue
1
Pages
10688-10688
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-024-54559-6
PMC
PMC11655867
OpenAlex
W4405509551
Cited by
57
References
6
Citations by year
2026: 36 · 2025: 21
FWCI
23.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
  • IRIS (submittedVersion, cc-by)
  • Open Access CRIS of the University of Bern
Funders
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030B_182834, 310030_204835, 4078P0_198470)
  • Fondation Leenaards
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
Keywords
inflammatory skin diseases, gene modules, immune pathways, Th17, type I interferon, neutrophilic dermatosis, eosinophilic dermatosis, precision medicine, personalized treatment, molecular diagnosis, gene expression profiles, treatment response prediction
MeSH terms
Humans, Inflammation, Skin, Skin Diseases, Th2 Cells, Gene Expression Profiling, Gene Regulatory Networks, Precision Medicine, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review